Uveitis and vitiligo associated with BCG treatment for malignant melanoma.
D000328:Adult; D000368:Aged; D001365:Axilla; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D007538:Isoniazid / Q000009:adverse effects* / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000000981:diagnostic imaging; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011859:Radiography; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D014605:Uveitis / Q000139:chemically induced*; D014820:Vitiligo / Q000139:chemically induced* / Q000473:pathology
D001500:BCG Vaccine; D007538:Isoniazid